EPISODE · Jul 29, 2025 · 40 MIN
Sarepta, Elevidys, and the Future of AAV Gene Therapy
from Biotech Blueprint · host Katerina Roznik
Subscribe to Biotech Blueprint HERE and to Biotech Capital Compass HERE.In this episode of the Biotech Blueprint podcast, I teamed up with the Biotech Capital Compass to break down Sarepta Therapeutics’ recent safety crisis, and what the FDA’s partial green light means for Elevidys, investor confidence, and the broader AAV field. We dig into the science, regulatory dynamics, and what might come next.
NOW PLAYING
Sarepta, Elevidys, and the Future of AAV Gene Therapy
No transcript for this episode yet
Similar Episodes
May 25, 2026 ·39m
May 17, 2026 ·37m